Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
- Registration Number
- NCT00595686
- Lead Sponsor
- Esanex Inc.
- Brief Summary
Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
- >18 years old
- Karnofsky performance status > 60
- confirmed hematological malignancy
- refractory to available therapy or for which no therapy is available
- adequate hepatic, renal and hematological function
Exclusion Criteria
- CNS malignancy
- at risk for prolonged QT interval
- significant GI/liver disease
- other serious concurrent illness or medical condition
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Single Arm SNX-5422 -
- Primary Outcome Measures
Name Time Method adverse events and other safety assessments continuous
- Secondary Outcome Measures
Name Time Method disease response specific to the hematological malignancy after every 2 cycles
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸Nashville, Tennessee, United States